IE
ROIV icon

Israel Englander’s Roivant Sciences ROIV Stock Holding History

Israel Englander’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,600
Closed -$130K – 6566
2023
Q4 		$130K Buy
+11,600
New +$113K ﹤0.01% 5275

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Israel Englander's ROIV Position: Q2 2026 in Review

Israel Englander reduced its Roivant Sciences (ROIV) stake by 13% in Q2 2026, selling an estimated $3.05M and leaving 700,494 shares worth $24.8M. The position accounts for 0.01% of the portfolio, ranked #1435.

Israel Englander first reported a position in ROIV in Q1 2022 and has held it in 15 quarters since. The position peaked at $39.2M in Q3 2025. 495 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Israel Englander held 700,494 shares of Roivant Sciences worth $24.8M as of Q2 2026.
  • Israel Englander sold 103,307 Roivant Sciences shares in Q2 2026, an estimated $3.05M.
  • Roivant Sciences made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1435 holding.
  • Israel Englander first reported a position in Roivant Sciences in Q1 2022 and has held it in 15 quarters since.
  • Israel Englander's Roivant Sciences position peaked at $39.2M in Q3 2025.
  • 495 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.